Innovation Pharmaceuticals Inc (IPIX)

[Justfactsmam]

Oh ... ok...you claim:

"Another key point to note is that in a 120 patient study a difference of 5% in absolute terms between the two arms on the primary endpoint would not be anywhere near statistically significant, and therefore neither arm will prove to be better than the other".

So 10%...15% or 20% would do it?...of course it would.

BUT YOU FAIL to acknowledge FDA was fully on board with Compassionate Use of Brilacidin after, and maybe before the end of the Clinical Trials...so since Drs requesting and receiving CU must report back to the FDA on impact... the FDA and IPIX know its impact of Brilacidin on the Critically Ill recipients of Brilacidin, which group has only a 5% survival rate...If 6 or 10 patients received Brilacidin via Compassionate Use and 3 or 5 survived...the question is ..." to what miracle would the FDA attribute an approximate 50% survival improvement?"

It's all speculation on my part (because Compassionate Use is not double-blinded)...but it should be noted that the FDA granting and encouraging (not stopping) Compassionate Use ... therefore, Compassionate Use results could be even more telling about Brilaicidin's attributes and efficacy...especially if the dosage was increased well beyond Clinical Trial protocol...

...all IMO...

We should learn a boatload in less than 7 trading days...

KNOW WHAT YOU OWN!